European Archives of Psychiatry and Clinical Neuroscience (2023) 273:1463–1476 https://doi.org/10.1007/s00406-023-01571-4 INVITED REVIEW Esmethadone‑HCl (REL‑1017): a promising rapid antidepressant Maurizio Fava1 · Stephen M. Stahl2,3 · Sara De Martin4 · Andrea...
Relmada Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to REL-1017.
Review ReportsVersions Notes Abstract Excessive Ca2+currents via N-methyl-D-aspartate receptors (NMDARs) have been implicated in many disorders. Uncompetitive NMDAR channel blockers are an emerging class of drugs in clinical use for major depressive disorder (MDD) and other neuropsychiatric diseases. ...